Does Gleason score of positive surgical margin after radical prostatectomy affect biochemical recurrence and oncological outcomes? Protocol for systematic review.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
24 03 2020
Historique:
entrez: 27 3 2020
pubmed: 27 3 2020
medline: 14 4 2021
Statut: epublish

Résumé

Positive surgical margins (PSM) in cancer patients are commonly associated with worse prognosis and a higher risk of secondary treatment. However, the relevance of this parameter in prostate cancer patients undergoing radical prostatectomy (RP) remains controversial, given the inconsistencies in its ability to predict biochemical recurrence (BCR) and oncological outcomes. Hence, further assessment of the utility of surgical margins for prostate cancer prognosis is required to predict these outcomes more accurately. Over the last decade, studies have used the Gleason score (GS) of positive margins to predict outcomes. Herein, the authors aim to conduct a systematic review investigating the role of GS of PSM after radical prostatectomy in predicting BCR and oncological outcomes. We will perform a search using MEDLINE, EMBASE, SCOPUS and COCHRANE databases. The review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will screen titles and abstracts to select articles appropriate for full-text review. Studies discussing GS of PSM after RP will be included. Given the change in reporting of GS, only articles from 2005 to 2019 will be included. The quality of the studies chosen will be assessed using the Newcastle Ottawa tool for non-randomised and Cochrane risk of bias for randomised control studies. We will adopt the grading of recommendations, assessment, development and evaluation framework to comment on quality of cumulative evidence. The primary outcome measure will be time to BCR. Secondary outcome measures include secondary treatment, disease-specific survival, disease progression-free and overall mortality at follow-up period. We aim to perform a meta-analysis if the level of heterogeneity is acceptable (I The review does not require ethics approval as it is a review of published literature. The findings of the review will be submitted for peer-reviewed publications and presented at scientific meetings. CRD42019131800.

Identifiants

pubmed: 32209629
pii: bmjopen-2019-034612
doi: 10.1136/bmjopen-2019-034612
pmc: PMC7199942
doi:

Substances chimiques

Androgen Antagonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e034612

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

J Clin Epidemiol. 2011 Apr;64(4):401-6
pubmed: 21208779
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Hum Pathol. 2012 Feb;43(2):254-60
pubmed: 21820147
Urology. 2010 Nov;76(5):1206-9
pubmed: 20692688
J Urol. 2016 Feb;195(2):337-42
pubmed: 26264998
J Urol. 2013 Apr;189(4):1302-7
pubmed: 23063630
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Eur Urol. 2014 Dec;66(6):1116-24
pubmed: 25052213
Int J Technol Assess Health Care. 2000 Autumn;16(4):1109-19
pubmed: 11155831
Am J Surg Pathol. 2017 Apr;41(4):e1-e7
pubmed: 28177964
BJU Int. 2012 Jun;109(12):1794-800
pubmed: 21992536

Auteurs

Athul John (A)

School of Medicine, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia atuljohn@gmail.com.
Urology, Central Adelaide local healthcare network, Adelaide, South Australia, Australia.

Michael O'Callaghan (M)

School of Medicine, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia.
Urology, South Australia Prostate Cancer Clinical Outcomes Collaborative, Adelaide, South Australia, Australia.
Flinders centre for innovation in Cancer, Flinders Unviersity, Adelaide, South Australia, Australia.

Rick Catterwell (R)

School of Medicine, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia.
Urology, Central Adelaide local healthcare network, Adelaide, South Australia, Australia.

Luke Selth (L)

School of Medicine, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH